| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrine Unit (J.S.F., R.M.N.), Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114; Department of Epidemiology (S.E.B., V.M., J.M.J., J.A.C., M.E.D.), University of Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Geriatrics (G.A.G.), University of California, Los Angeles, School of Medicine, Los Angeles, California 90095; Departments of Epidemiology and Biostatistics (M.R.S.), School of Public Health, University of Michigan, Ann Arbor, Michigan 48109; and Division of Research (B.E., J.C.L.), Kaiser Permanente Northern California, Oakland, California 94612
Address all correspondence and requests for reprints to: Joel S. Finkelstein, M.D., Endocrine Unit, Thier 1051, Massachusetts General Hospital, 50 Blossom Street, Boston, Massachusetts 02114. E-mail: jfinkelstein{at}partners.org.
| Abstract |
|---|
|
|
|---|
Objective: Our objective was to assess rates of bone loss at each stage of the transition and examine major factors that modify those rates.
Design, Setting, and Participants: We conducted a longitudinal cohort study of 1902 African-American, Caucasian, Chinese, or Japanese women participating in The Study of Womens Health Across the Nation. Women were pre- or early perimenopausal at baseline.
Outcome Measure: We assessed bone mineral density (BMD) of the lumbar spine and total hip across a maximum of six annual visits.
Results: There was little change in BMD during the pre- or early perimenopause. BMD declined substantially in the late perimenopause, with an average loss of 0.018 and 0.010 g/cm2·yr from the spine and hip, respectively (P < 0.001 for both). In the postmenopause, rates of loss from the spine and hip were 0.022 and 0.013 g/cm2·yr, respectively (P < 0.001 for both). During the late peri- and postmenopause, bone loss was approximately 35–55% slower in women in the top vs. the bottom tertile of body weight. Apparent ethnic differences in rates of spine bone loss were largely explained by differences in body weight.
Conclusions: Bone loss accelerates substantially in the late perimenopause and continues at a similar pace in the first postmenopausal years. Body weight is a major determinant of the rate of menopausal BMD loss, whereas ethnicity, per se, is not. Healthcare providers should consider this information when deciding when to screen women for osteoporosis.
| Introduction |
|---|
|
|
|---|
Despite the public health importance of postmenopausal osteoporosis, there are important gaps in our knowledge of the effect of the menopause transition on the skeletal system. Although bone loss accelerates after menses cease (3, 4, 5), it is not clear either when bone loss begins or what the rates of bone loss are at various stages of the menopause transition. It is important to determine when bone loss accelerates so that women and their health care providers can make informed decisions regarding the appropriate time to screen for osteoporosis and to consider therapy to prevent bone loss. There is considerable variation in rates of bone loss among women, with some women experiencing rapid bone loss during the menopause transition and others experiencing little or no bone loss (3, 5, 6). The basis for this variation is poorly understood. Identifying factors that are associated with rapid or slow rates of bone loss during the menopause transition could assist clinicians in making decisions that will optimize skeletal health in midlife women.
The Study of Womens Health Across the Nation (SWAN) is a seven-center, longitudinal cohort study of the menopause transition in a community-based sample of women from multiple ethnic groups. Bone mineral density (BMD) of the lumbar spine and proximal femur has been measured annually in women at five SWAN sites. SWAN is the first large-scale, multiethnic, longitudinal cohort study to assess BMD across the entire menopause transition. Thus, SWAN provides a unique opportunity to characterize changes in BMD across the menopause transition and to assess factors that influence those changes.
| Subjects and Methods |
|---|
|
|
|---|
SWAN is a seven-site, longitudinal cohort study in community-based groups of women. At baseline, 3302 pre- or early perimenopausal women who belonged to one of five ethnic/racial groups were recruited: Caucasian (n = 1550), African-American (n = 935), Japanese (n = 281), Chinese (n = 250), and Hispanic (n = 286). Race/ethnicity was determined by self-report. Participants were enrolled at seven clinical sites in Boston, Chicago, Detroit area, Los Angeles, Hudson County (NJ), Oakland, and Pittsburgh. All seven sites enrolled Caucasians, and each site also enrolled women belonging to one prespecified minority ethnic group. Eligibility criteria for entry into the SWAN longitudinal cohort were age 42–52 yr, intact uterus and at least one ovary, no current use of estrogens or other medications known to affect ovarian function, at least one menstrual period in the 3 months before screening, and self-identification as a member of one of the five eligible ethnic groups. Recruitment techniques were designed to generate a representative sample of women at each of the seven sites. Eligibility criteria and cohort recruitment have been described in detail (7). The Chicago and Hudson County, NJ, sites did not measure BMD, leaving a potential maximum of 2413 Caucasian, African-American, Japanese, or Chinese women for BMD analyses. Of these women, 1902 had a usable baseline BMD measurement and at least one follow-up exam and are included in this report.
Determination of menopause stage
At each annual visit, menopause stage was determined based on reports about frequency and regularity of menstrual bleeding. Women were classified as premenopausal if they had experienced at least one menstrual period in the last 3 months with no change in the regularity of their menstrual bleeding during the last year. Women were classified as early perimenopausal if they had experienced at least one menstrual period in the last 3 months with some change in the regularity of their menstrual bleeding during the last year. Women were classified as late perimenopausal if they had experienced no menstrual bleeding in the last 3 months but some menstrual bleeding during the last 11 months. Women were classified as postmenopausal once they had experienced at least 12 consecutive months of amenorrhea. The postmenopausal stage was defined as beginning at the time of the womans final menstrual period. Once a woman had transitioned to a more advanced menopause stage, she was not reclassified into an earlier stage.
Study protocol
All subjects were seen at a SWAN center for annual measurements of BMD of the lumbar spine and proximal femur, assessment of factors possibly related to BMD using questionnaires, and measurement of height and weight. Standardized interviewer-administered or self-administered questionnaires were used to assess the following parameters: age (years), cigarette smoking, alcohol intake (drinks per day), vitamin D (International units per day), and calcium intake (milligrams per day) (8), medication use, and menopause stage. The protocol was approved by the Institutional Review Board at each center, and all women provided written informed consent.
Assessment of BMD
BMD of the posterior-anterior lumbar spine and total hip was measured by dual-energy x-ray absorptiometry (DXA) using a Hologic QDR 2000 densitometer (Hologic Inc., Waltham, MA) in Pittsburgh and Oakland or a Hologic QDR 4500A densitometer in Boston, Detroit area, and Los Angeles.
All five centers employed a standard quality control program that included daily measurement of a Hologic anthropomorphic spine phantom at each site, cross-site calibration with a single anthropomorphic spine phantom, visual review of every scan image by a local site investigator experienced in bone densitometry, and random review of 5% of scans plus all problem scans by Synarc, Inc. (Waltham, MA). Measurements of the local spine phantoms and the circulating spine phantom were analyzed by Synarc and used to adjust DXA measurements for minor temporal or geographic variations. Our short-term in vivo measurement SD values are 0.014 g/cm2 (1.4%) and 0.016 g/cm2 (2.2%) for the lumbar spine and femoral neck.
Data analysis
The primary goal of this study was to estimate and then compare rates of change of lumbar spine and total hip BMD across the four menopause stages. The rate of change in BMD during each stage was estimated using linear mixed models. Repeated measures of BMD were modeled as a function of four separate time variables, one for the cumulative amount of time spent in each of the four menopause stages. The algorithm used to determine the cumulative amount of time spent in each menopause stage is described in the Appendix (published as supplemental data on The Endocrine Societys Journals Online web site at http://jcem.endojournals.org). Regression coefficients for these four time variables provided estimates of the annual change in BMD within each menopause stage. Models were adjusted for baseline age, menopause stage, weight, smoking, calcium intake, vitamin D intake, and alcohol intake; percent change in weight since baseline; ethnicity; and SWAN clinical site. Estimated rates of BMD change across menopause stages, weight tertiles, and ethnic groups were compared using suitable contrasts.
Because body weight and ethnicity were powerful predictors of baseline BMD in these women (9), we performed additional analyses to isolate the effects of these variables on rates of change of BMD in each menopause stage. First, interaction terms between ethnicity and each of the four time variables were tested to determine whether rates of change within each stage varied across ethnic groups. As has been done previously (9), these analyses were also performed on a subset of the population in which there was considerable overlap of body weight among all four ethnic groups (50–78 kg). This subset contained 1133 women (587 Caucasians, 198 African-Americans, 181 Japanese, and 167 Chinese). Because there were still weight differences between ethnic groups in the restricted sample, models were still adjusted for the variables listed above, including weight. Second, interaction terms between baseline weight tertiles and each of the four time variables were tested to determine the effect of weight on rates of change in each menopause stage. This analysis was then stratified by ethnicity to assess the effect of weight on rates of change within each ethnic group separately. For these latter analyses, weight tertiles were generated using cutoff points specific to each ethnic group.
Data were censored at the time a participant started hormone or other antiresorptive therapy (including bisphosphonates, calcitonin, raloxifene, or tamoxifen), had GnRH agonist therapy, had two consecutive visits in which she reported recent glucocorticoid use, or underwent a hysterectomy or bilateral oophorectomy.
| Results |
|---|
|
|
|---|
The clinical characteristics of the entire cohort (n = 1902) and the four ethnic groups are shown in Table 1
. On average, African-American women were 9 kg heavier than Caucasians and 26–27 kg heavier than Chinese and Japanese women. Median calcium intake was highest in Caucasian women.
|
Rates of change in BMD in various menopause stages
Figure 1
shows the annual rate of change in lumbar spine and total hip BMD, adjusted for covariates, in each menopause stage for the entire cohort. There was little change in lumbar spine or total hip BMD during the pre- or early perimenopause. Bone loss accelerated markedly in the late perimenopause, with an average loss of 0.018 g/cm2·yr (1.6%) and 0.010 g/cm2·yr (1.0%) from the spine and hip, respectively (P < 0.001 for both). In postmenopausal women, rates of spine and hip bone loss were 0.022 g/cm2·yr (2.0%) and 0.013 g/cm2·yr (1.4%), respectively (P < 0.001 for both). Ethnicity, baseline weight, and change in weight since baseline were significantly associated with lumbar spine BMD. Ethnicity, baseline weight, change in weight since baseline, smoking, baseline menopause stage, and clinical site were significantly associated with hip BMD.
|
Figure 2
shows the annual rate of change in lumbar spine BMD, adjusted for covariates, during each menopause stage for each ethnic group. As in the whole cohort, BMD loss accelerated markedly in the late perimenopause in each ethnic group. In general, lumbar spine BMD loss was most rapid in Japanese and Chinese women, intermediate in Caucasian women, and slowest in African-American women during the late perimenopause and postmenopause (Fig. 2A
; P < 0.001 for ethnic differences in late peri- and postmenopausal rates). When the analysis was constrained to a subset of the cohort in which there was considerable overlap of body weight among all four ethnic groups, ethnic differences in rates of late peri- and postmenopausal spine BMD loss were eliminated (Fig. 2B
; P = 0.37 and P = 0.11 for the late peri- and postmenopause, respectively).
|
Figure 3
shows the annual rates of change in lumbar spine and total hip BMD, adjusted for covariates, during each menopausal stage by tertile of baseline body weight. In each weight tertile, BMD loss accelerated substantially in the late perimenopause. There were significant differences in rates of late peri- and postmenopausal spine BMD loss across weight tertiles (P < 0.001 for both). Rates of postmenopausal hip BMD loss also differed significantly across weight tertiles (P < 0.001). BMD loss was most rapid in women in the lowest tertile of body weight and slowest in women in the highest tertile of body weight. In late peri- and postmenopausal women, rates of spine and hip bone loss were approximately 35–55% slower in women in the top tertile vs. the bottom tertile of body weight. Similar patterns of bone loss in relation to weight tertiles were observed for the lumbar spine (Fig. 4
) and total hip (data not shown) in African-American, Caucasian, and Chinese women but not in Japanese women.
|
|
| Discussion |
|---|
|
|
|---|
Weight and ethnicity were powerful apparent modifiers of the rate of BMD loss. Because weight and ethnicity were strongly related, we used two strategies to isolate their impact. First, we performed stratified analyses in which the effect of weight was examined in each ethnic group. As in the full cohort, rates of late perimenopausal and postmenopausal bone loss were significantly slower in both African-American and Caucasian women in the highest than in the lowest tertile of body weight. This finding demonstrates that the effect of weight on rates of bone loss was independent from ethnicity. The failure to find an effect of weight in the Chinese or Japanese women is likely because these women tended to be of a very homogeneous, light weight thus making it unlikely to see slowing of loss in the upper tertile. Moreover, the number of Japanese and Chinese women in each weight tertile of the late peri- and postmenopause is so small that the estimates of rates of bone loss may be unstable. It is possible, however, that the relationship between weight and rates of bone loss varies by ethnicity. Additional data are needed to clarify this issue. Second, the effect of ethnicity was examined in a sub-cohort of women selected to maximize the overlap of body weight across ethnic groups. Whereas rates of spine BMD loss tended to be slower in African-Americans and higher in Asians in the whole cohort, these differences were largely eliminated when analyses were restricted to women with more homogenous body weights. Thus, ethnicity did not appear to have an independent effect on rates of bone loss.
The effect of the menopause transition on changes in BMD has been assessed in both cross-sectional and longitudinal studies, but findings have been inconsistent. Some cross-sectional studies report that bone mass of the spine or proximal femur is lower in perimenopausal than in premenopausal women (11, 12, 13, 14, 15), whereas others have not detected any differences in BMD before the menopause (4, 16). Some longitudinal studies of pre- or early perimenopausal women failed to detect significant decreases in spine, radius, or total-body BMD (17, 18, 19, 20) whereas others have reported that BMD of the radius (19, 21), femoral neck (22, 23, 24), and spine (17, 22, 23, 24) declines during the perimenopause. Existing longitudinal studies of menopausal bone loss have important limitations, however. Most previous studies are relatively small, lack ethnic diversity, and measured BMD with insensitive and/or imprecise techniques such as single-photon absorptiometry (SPA) (25) or dual-photon absorptiometry, thereby limiting the ability to asses changes in BMD. In a group of Australian women followed for 2 yr, BMD loss was fastest in women who became postmenopausal, next fastest in women who became late perimenopausal, and undetectable in pre- and early perimenopausal women (24). Two studies have examined changes in BMD across the entire menopause transition (20, 23). Ahlborg et al. (20) measured forearm BMD using SPA in 156 Caucasian women every other year from age 48–64 yr. They failed to detect a decline in BMD before the final menstrual period, probably because SPA is not a sensitive technique for detecting bone loss. Recker et al. (23) measured BMD of the spine, femoral neck, and total body annually for an average of 9.5 yr in 75 women who were premenopausal and at least 46 yr old (mean age 49 yr). During the first 3 yr, measurements were made using dual-photon absorptiometry. Subsequently, measurements were made using two different DXA machines. BMD changed in a sigmoid pattern with loss beginning 2–3 yr before the final menstrual period and ending 3–4 yr after the final menstrual period. The small sample size and the changes in measurement technique limit interpretation of these data, however.
After the menopause, some women lose bone much more rapidly than others (3, 5, 6). For example, forearm bone loss may vary from 0–50% in the first 6–8 yr after menopause (26). It is unclear why some postmenopausal women lose bone rapidly, whereas others lose bone slowly. Several studies have found that higher body mass index and weight are associated with slower rates of peri- and postmenopausal bone loss (3, 24, 26, 27). Weight change has also been associated with changes in BMD (28). Weight was also a powerful determinant of bone loss in our women, and its effect was independent from ethnicity. Based on these results, clinicians should be particularly aware of the risk of bone loss in women who are thin.
The reasons why higher body weight is associated with slower rates of bone loss are unknown. Osteocytes are thought to sense mechanical loading of the skeleton (29). It is possible that in response to greater mechanical loading, osteocytes send signals to other bone cells that either reduce osteoclastic bone resorption, as evidenced by an inverse association between bone turnover and BMI (27), or increase osteoblastic bone formation resulting in an attenuation of bone loss in heavier women. Increased production of estrogens by adipose tissue may also contribute to the association between BMD and body weight. Alternatively, it is possible that the apparent inverse relationship between changes in BMD and body weight is related, at least in part, to technical limitations of DXA technology. Simulations using phantoms suggest that measured BMD is related to the extraosseous soft tissue composition, the mix of red to yellow marrow within the bone being measured, and the homogeneity of soft tissue in the region of interest (30, 31). Moreover, these simulations suggest that the degree of DXA artifact is related to the extraosseous soft tissue composition so that BMD will appear to decrease more slowly in subjects with more soft tissue fat and vice versa (30, 31). Because estimations of the relationship between BMD and fracture risk have also included these potential artifacts, however, the prognostic value of BMD data for fracture prediction likely remains clinically relevant.
There is a wide disparity in BMD, bone turnover, and fracture incidence across ethnic groups (9, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42). Ethnic differences in BMD may reflect differences in peak BMD, rates of bone loss, or both. African-American women have higher cortical and trabecular BMD than Caucasians, and this difference may account for their decreased incidence of osteoporotic fractures (32, 33, 35, 36, 37, 38, 43, 44). We previously found similar differences in lumbar spine and proximal femur BMD between pre- and early perimenopausal African-American and Caucasian women in SWAN, although these differences were attenuated when women were matched for body weight (9). Like African-Americans, Chinese and Japanese women have lower hip and spine fracture rates than Caucasians (39, 40, 41, 45, 46), even though they also have lower BMD if body size is not taken into account (46, 47, 48, 49, 50). In SWAN, we also found that unadjusted spine and femoral neck BMDs were higher in Caucasians than in Chinese and Japanese women (9). After adjustment for body weight, however, femoral neck BMD was similar in Asian and Caucasian women, and spine BMD was actually lower in Caucasian women (9). Thus, fracture rates may be higher in Caucasians than in African-American or Asian women because of lower peak premenopausal BMDs for their weight.
Although many studies have examined bone loss in Caucasian women, very little is known about changes in BMD in non-Caucasian women. Cross-sectional data suggest that radial BMD may decrease more slowly in postmenopausal African-American than Caucasian women, whereas rates of spine bone loss are similar (37). In contrast, one longitudinal study suggested that bone loss from the hip was actually more rapid in elderly African-American women than in elderly Caucasians (51). Limited longitudinal data suggest that BMD begins to decline in perimenopausal Japanese women (50, 52, 53, 54, 55, 56). As in Caucasian women, the rate of bone loss in Japanese women is inversely related to body weight (54). No previous studies have directly compared longitudinal rates of bone loss across multiple ethnic groups. The present data demonstrate that apparent ethnic differences in rates of BMD loss during the menopause transition are largely due to ethnic differences in body weight.
Some limitations of this study deserve mention. Although we followed women for up to 5 yr, we could not capture the entire menopause transition in many women. A longer period of follow-up will allow assessment of BMD across the entire menopause transition in most all women in the future. BMD was assessed annually. More frequent measurements would have allowed a more precise and detailed description of patterns of bone loss during the transition.
Our findings may have important clinical implications. Most published guidelines do not recommend routine screening of women for osteoporosis until age 65 (57). However, like BMD (58, 59), the rate of bone loss is an independent predictor of fracture risk in postmenopausal women (60, 61, 62). Because the rate of BMD loss accelerates markedly in the late perimenopause, our data suggest that clinicians should consider measuring BMD once a woman has experienced 3 months of amenorrhea. Intervention may be warranted if a woman has relatively low BMD at the beginning of the menopause transition and is beginning to lose bone rapidly. Clinicians should be particularly wary of the risk for rapid bone loss in late perimenopausal women with low body weight. The finding of accelerated BMD loss in the lightest women adds important support for the recommendation included in several published guidelines that screening bone densitometry should be done at an earlier age in thin women (57). The cost-effectiveness of a broader BMD screening program needs to be assessed.
In conclusion, there is little if any change in BMD in midlife pre- or early perimenopausal women. BMD loss increases substantially in the late perimenopause and remains rapid in the first few postmenopausal years. Body weight is an important determinant of the rates of BMD loss during the menopause transition. These findings suggest that healthcare providers should consider screening for osteoporosis when women enter the late stages of the menopause transition, particularly if they have relatively low body weight.
| Acknowledgments |
|---|
We thank the study staff at each site and all the women who participated in SWAN.
| Footnotes |
|---|
Disclosure Statement: J.S.F. is on the Speakers Bureau for Merck & Co. and Novartis Pharmaceuticals and has research support from Solvay Pharmaceuticals, AstraZeneca Pharmaceuticals LP, and Ardana Bioscience Ltd. B.E. is a consultant for Procter and Gamble, GlaxoSmithKline, Roche Pharmaceuticals, and Barr Pharmaceuticals; has received lecture fees from Eli Lilly & Co. and Barr Pharmaceuticals; and has research support from Procter and Gamble. J.A.C. is a consultant for Eli Lilly & Co. and Novartis Pharmaceuticals, is on the Speakers Bureau for Merck & Co., and has received research support from Merck & Co., Eli Lilly & Co., Pfizer Inc., and Novartis Pharmaceuticals. M.R.S. has received lecture fees from Wyeth Pharmaceuticals. The remaining authors have nothing to disclose.
First Published Online December 26, 2007
Abbreviations: BMD, Bone mineral density; DXA, dual-energy x-ray absorptiometry; SPA, single-photon absorptiometry; SWAN, Study of Womens Health Across the Nation.
Received August 22, 2007.
Accepted December 19, 2007.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
W. W Wong, R. D Lewis, F. M Steinberg, M. J Murray, M. A Cramer, P. Amato, R. L Young, S. Barnes, K. J Ellis, R. J Shypailo, et al. Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial Am. J. Clinical Nutrition, November 1, 2009; 90(5): 1433 - 1439. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Cooper BMBCh PhD Our approach to osteoporosis screening and treatment needs to change Can. Med. Assoc. J., June 17, 2008; 178(13): 1683 - 1684. [Full Text] [PDF] |
||||
Read all eLetters
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |